RU2731908C2 - Композиции апилимода и способы его использования при лечениии меланомы - Google Patents

Композиции апилимода и способы его использования при лечениии меланомы Download PDF

Info

Publication number
RU2731908C2
RU2731908C2 RU2017119064A RU2017119064A RU2731908C2 RU 2731908 C2 RU2731908 C2 RU 2731908C2 RU 2017119064 A RU2017119064 A RU 2017119064A RU 2017119064 A RU2017119064 A RU 2017119064A RU 2731908 C2 RU2731908 C2 RU 2731908C2
Authority
RU
Russia
Prior art keywords
apilimod
melanoma
present
vemurafenib
treatment
Prior art date
Application number
RU2017119064A
Other languages
English (en)
Russian (ru)
Other versions
RU2017119064A3 (enExample
RU2017119064A (ru
Inventor
Хенри ЛИХЕНШТЕЙН
Джонатан М. РОТБЕРГ
Тянь СЮЙ
Крис КОНРАД
Пол БЕКЕТТ
Шон ЛАНДРЕТТЕ
София ГЕЙЛ
Нил БИХАРРИ
Original Assignee
ЭйАй ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭйАй ТЕРАПЬЮТИКС, ИНК. filed Critical ЭйАй ТЕРАПЬЮТИКС, ИНК.
Publication of RU2017119064A publication Critical patent/RU2017119064A/ru
Publication of RU2017119064A3 publication Critical patent/RU2017119064A3/ru
Application granted granted Critical
Publication of RU2731908C2 publication Critical patent/RU2731908C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2017119064A 2014-11-07 2015-11-06 Композиции апилимода и способы его использования при лечениии меланомы RU2731908C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US62/077,127 2014-11-07
US201562115228P 2015-02-12 2015-02-12
US62/115,228 2015-02-12
US201562119540P 2015-02-23 2015-02-23
US62/119,540 2015-02-23
PCT/US2015/059502 WO2016073871A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of melanoma

Publications (3)

Publication Number Publication Date
RU2017119064A RU2017119064A (ru) 2018-12-10
RU2017119064A3 RU2017119064A3 (enExample) 2019-06-03
RU2731908C2 true RU2731908C2 (ru) 2020-09-09

Family

ID=54548301

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2017119064A RU2731908C2 (ru) 2014-11-07 2015-11-06 Композиции апилимода и способы его использования при лечениии меланомы
RU2017119066A RU2739992C2 (ru) 2014-11-07 2015-11-06 Композиции апилимода и способы их применения в лечении колоректального рака

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017119066A RU2739992C2 (ru) 2014-11-07 2015-11-06 Композиции апилимода и способы их применения в лечении колоректального рака

Country Status (16)

Country Link
US (2) US20190209576A1 (enExample)
EP (3) EP3215157B8 (enExample)
JP (2) JP6716585B2 (enExample)
KR (2) KR20170101907A (enExample)
CN (2) CN107206090A (enExample)
AU (2) AU2015342863B2 (enExample)
BR (2) BR112017009000A2 (enExample)
CA (2) CA2966334A1 (enExample)
ES (1) ES2734081T3 (enExample)
HU (1) HUE044153T2 (enExample)
IL (2) IL251903B (enExample)
MX (2) MX374385B (enExample)
PL (1) PL3215157T3 (enExample)
PT (1) PT3215157T (enExample)
RU (2) RU2731908C2 (enExample)
WO (2) WO2016073871A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6855243B2 (ja) 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
GB201408100D0 (en) * 2014-05-07 2014-06-18 Sec Dep For Health The Detection method
KR20170098812A (ko) 2014-11-07 2017-08-30 램 테라퓨틱스, 인코포레이티드 신장암의 치료에 사용하기 위한 아필리모드
AU2017210324A1 (en) * 2016-01-21 2018-08-16 AI Therapeutics, Inc. Biomarkers for treating cancer with apilimod
US20190365771A1 (en) * 2016-10-12 2019-12-05 AI Therapeutics, Inc. Apilimod compositions and methods for using same in the treatment of alzheimer's disease
WO2018134254A1 (en) 2017-01-17 2018-07-26 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
JP7354123B2 (ja) 2018-02-21 2023-10-02 エイアイ・セラピューティクス・インコーポレーテッド アピリモドとグルタミン酸作動薬を用いた併用療法
MX2022008627A (es) 2020-01-13 2022-11-08 Verge Analytics Inc Pirazolo-pirimidinas sustituidas y usos de las mismas.
KR20240075774A (ko) * 2021-06-11 2024-05-29 오르파이 테라퓨틱스 인코포레이티드 안정화된 아필리모드 조성물 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693097B2 (en) * 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
NZ584288A (en) 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
WO2005112938A2 (en) * 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
AU2005282241B2 (en) 2004-09-08 2011-03-03 Chelsea Therapeutics, Inc. Quinazoline derivatives as metabolically inert antifolate compounds.
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) * 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
PT2385053E (pt) 2005-11-17 2013-12-17 Osi Pharm Inc Intermediários para a preparação de compostos bicíclicos condensados como inibidores mtor
CA2658394C (en) 2006-07-12 2016-08-16 University Of Tennessee Research Foundation Substituted acylanilides and methods of use thereof
RU2438664C2 (ru) * 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
WO2011146727A1 (en) * 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9295731B2 (en) * 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
JP6855243B2 (ja) * 2014-01-24 2021-04-07 エイアイ・セラピューティクス・インコーポレーテッド 癌治療のためのアピリモド（ａｐｉｌｉｍｏｄ）組成物
KR20170098812A (ko) * 2014-11-07 2017-08-30 램 테라퓨틱스, 인코포레이티드 신장암의 치료에 사용하기 위한 아필리모드
US20180015098A1 (en) * 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
US20180078561A1 (en) * 2015-03-31 2018-03-22 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Краткий курс молекулярной фармакологии под ред. П.В.Сергеева, М., 1975, с.10. *
Краткий курс молекулярной фармакологии под ред. П.В.Сергеева, М., 1975, с.10. Холодов Л.Е. и др. Клиническая фармакокинетика. М., "Медицина", 1985, с. 83-98, 134-138, 160, 378-380. Харкевич Д.А. Фармакология: Учебник, 2010, 10-е издание, стр.72-82. *
Харкевич Д.А. Фармакология: Учебник, 2010, 10-е издание, стр.72-82. *
Холодов Л.Е. и др. Клиническая фармакокинетика. М., "Медицина", 1985, с. 83-98, 134-138, 160, 378-380. *

Also Published As

Publication number Publication date
JP6716585B2 (ja) 2020-07-01
RU2017119066A (ru) 2018-12-07
US20170333439A1 (en) 2017-11-23
CN107427522A (zh) 2017-12-01
RU2017119064A3 (enExample) 2019-06-03
BR112017009265A2 (pt) 2017-12-19
EP3215157A1 (en) 2017-09-13
RU2739992C2 (ru) 2020-12-30
PL3215157T3 (pl) 2019-11-29
KR20170101907A (ko) 2017-09-06
EP3954375A1 (en) 2022-02-16
CN107206090A (zh) 2017-09-26
RU2017119066A3 (enExample) 2019-06-07
MX374385B (es) 2025-03-06
WO2016073884A1 (en) 2016-05-12
WO2016073871A1 (en) 2016-05-12
AU2015342863A1 (en) 2017-06-15
CN107427522B (zh) 2021-06-15
MX2017006019A (es) 2017-09-13
HUE044153T2 (hu) 2019-09-30
JP2017535600A (ja) 2017-11-30
ES2734081T3 (es) 2019-12-04
IL251903A0 (en) 2017-06-29
PT3215157T (pt) 2019-07-12
MX2017006026A (es) 2017-06-19
BR112017009000A2 (pt) 2017-12-19
EP3215159A1 (en) 2017-09-13
JP6768682B2 (ja) 2020-10-14
EP3215157B1 (en) 2019-04-10
KR20170098813A (ko) 2017-08-30
EP3215159B1 (en) 2021-07-21
JP2017533963A (ja) 2017-11-16
IL251904B (en) 2021-03-25
AU2015342876B2 (en) 2020-07-09
US10765682B2 (en) 2020-09-08
US20190209576A1 (en) 2019-07-11
AU2015342876A1 (en) 2017-06-15
CA2966356A1 (en) 2016-05-12
RU2017119064A (ru) 2018-12-10
IL251903B (en) 2021-05-31
IL251904A0 (en) 2017-06-29
AU2015342863B2 (en) 2021-01-21
EP3215157B8 (en) 2019-05-22
CA2966334A1 (en) 2016-05-12

Similar Documents

Publication Publication Date Title
US11266654B2 (en) Apilimod compositions and methods for using same
RU2731908C2 (ru) Композиции апилимода и способы его использования при лечениии меланомы
CN107249638B (zh) 阿匹莫德用于治疗肾癌
WO2016160102A1 (en) Active metabolites of apilimod and uses thereof
HK1242204B (en) Apilimod for use in the treatment of melanoma
HK1242204A1 (en) Apilimod for use in the treatment of melanoma
HK1242965B (en) Apilimod for use in the treatment of colorectal cancer
NZ722491B2 (en) Apilimod compositions and methods for using same
HK1226329B (en) Apilimod compositions for treating non-hodgkin's b cell lymphoma

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant